drugset / Trial / NCT01569815

Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function

NCT01569815

Phase 1 Completed 32 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to determine the multiple dose pharmacokinetics of LCZ696 and its metabolites in subjects with mild to moderate renal impairment and to evaluate the safety of LCZ696 in this population.

Timeline

Start
2009-02
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject LCZ696 Unknown 400 mg

Indications

No indication recorded.